registration of Rigvir
registration of medicine RIGVIR
European Medicine Agency Cancer
European Union registration
melanoma
EMA
Latvia
initial feasibility study
unique anti-cancer medicine
cancer medicines
H2020-SMEInst
subsequent clinical trials necessary
EU regulations
phase of H2020
dangerous life-threatening disorders
basis
medicinal product
financial support
non-pathogenic virus
significant costs
resources
humanity
various cancers
promising medical future
application
number of therapies available
front-line treatment
process
Georgia
use
commercialisation
Armenia
purpose
novo
Latima SIA
National registrations
treatments
virotherapy